Pharmacodynamics of ziprasidone in children and adolescents: Impact on dopamine transmission

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 42, Issue 8, 2003, Pages 902-907

  Sallee, Floyd R ^a   Gilbert, Donald L ^a   Vinks, Alexander A ^a   Miceli, Jeffrey J ^b   Robarge, Lisa ^b   Wilner, Keith ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

Dopamine; Serotonin; Tourette; Ziprasidone

Indexed keywords

DOPAMINE; PROLACTIN; ZIPRASIDONE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG ACTIVITY; DRUG MECHANISM; EYELID REFLEX; GILLES DE LA TOURETTE SYNDROME; HUMAN; NEUROTRANSMISSION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHOOL CHILD; TIC; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM; PREFRONTAL CORTEX;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHRONIC DISEASE; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PIPERAZINES; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D2; THIAZOLES; TOURETTE SYNDROME;

EID: 0042330156     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CHI.0000046897.27264.46     Document Type: Article

References (36)

1. Alexander GE, DeLong MR, Strick PL (1986), Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357-381
2. American Psychiatric Association (1994), Diagnostic and Statistical Manual for Psychiatry, edition 4 (DSM-IV). Washington, DC: American Psychiatric Association
3. Anca MH, Giladi N, Korczyn AD (2001), Ropinirole for Tourette syndrome. Neurology 56:A121
4. Barbato G, Ficca G, Muscettola G, Fichele M, Beatrice M, Rinaldi F (2000), Diurnal variation in spontaneous eye-blink rate. Psychiatry Res 93:145-151
5. Barnes NM, Sharp T (1999), A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152
6. Bench CJ, Lammertsma AA, Grasby PM et al (1996), The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacologia 124:141-147
7. Black KJ, Mink JW (2000), Response to levodopa challenge in Tourette syndrome. Mov Disord 15:1194-1198
8. Bruggeman R, van dL, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA (2001), Risperidone versus pimozide in Tourettes disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62:50-56
9. Campbell KM, de Lecea L, Severynse DM et al (1999), OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 19:5044-5053
10. Caplan R, Guthrie D, Komo S (1996), Blink rate in children with attention-deficit-hyperactivity disorder. Biol Psychiatry 39:1032-1038
11. Chappell PB, Scahill LD, Leckman JF (1997), Future therapies of Tourette syndrome. Neurol Clin 15:429-450
12. David SR, Taylor CC, Kinon BJ, Breier A (2000), The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085-1096
13. Dion Y, Annable L, Sandor P, Chouinard G (2002), Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31-39
14. Feinberg M, Carroll BJ (1979), Effects of dopamine agonists and antagonists in Tourette's disease. Arch Gen Psychiatry 36:979-985
15. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR (2003), Tic reduction with pergolide in a randomized controlled trial in children. Neurology 60:606-611
16. Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR (2000), Tourette syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 54:1310-1315
17. Griesemer DA (1997), Pergolide in the management of Tourette syndrome. J Child Neurol 12:402-403
18. Hamelin BA, Allard S, Laplante L et al (1998), The effect of timing of a Standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18:9-15
19. Janiszewski JS, Fouda HG, Cole RO (1995), Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. J Chromatogr Biomed Appl 668:133-139
20. Karson CN, Burns RS, LeWitt PA, Foster NL, Newman RP (1984), Blink rates and disorders of movement. Neurology 34:677-678
21. Kleven MS, Koek W (1996), Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther 279:1211-1219
22. Lipinski JF, Sallee FR, Jackson C, Sethuraman G (1997), Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 12:402-407
23. Mackert A, Flechtner KM, Woyth C, Frick K (1991), Increased blink rates in schizophrenics: influences of neuroleptics and psychopathology. Schizophrenia Res 4:41-47
24. Markianos M, Hatzimanolis J, Lykouras L (2001), Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 251:141-146
25. Masi G, Cosenza A, Mucci M (2001), Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11:389-394
26. Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N (2000), Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 49(suppl):5-13
27. Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ (2000), Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 49(suppl):49-56
28. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000), 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237
29. Sallee FR, Kurlan R, Goetz CG et al (2000), Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299
30. Seeger TF, Seymour PA, Schmidt AW et al (1995), Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
31. Singer HS (1997), Neurobiology of Tourette syndrome. Neurol Clin 15:357-379
32. Taylor JR, Elsworth JD, Lawrence MS, Sladek JR Jr, Roth RH, Redmond DE Jr (1999), Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys. Exp Neurol 158:214-220
33. Tourette Syndrome Study Group (2002), Treatment of ADHD in children with tics. Neurology 58:527-536
34. Tulen JH, Azzolini M, de Vries JA, Groeneveld WH, Passchier J, van De Wetering BJ (1999), Quantitative study of spontaneous eye blinks and eye tics in Gilles de la Tourette's syndrome. J Neurol Neurosurg Psychiatry 67:800-802
35. Ziemann U, Bruns D, Paulus W (1996), Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci Lett 208:187-190
36. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W (1997), Changes in human motor cortex excitability induced by dopaminergic and antidopaminergic drugs. Electroencephalogr Clin Neurophysiol 105:430-437